Institute for Health Metrics and Evaluation

Cardio Diagnostics Holdings, Inc and Aimil Ltd Join Forces to Introduce Cardiovascular Epigenetic Technologies to India

Retrieved on: 
Tuesday, October 17, 2023
Technology, Medical Devices, General Health, Science, Genetics, Medical Supplies, Clinical Trials, Cardiology, Biotechnology, Health, Health Technology, Other Science, Research, Other Technology, Software, Other Health, Artificial Intelligence, Cardiovascular disease, Sumathi Best Television Current Reporting Award, Death, Distribution, Prevalence, Organization, Calibration, CCTA, Radiation, Cardio, R, Laboratory, CVD, Global Burden of Disease Study, Artificial intelligence, Entrepreneurship, CHD, Growth, Supply, Evaluation, NABL, Moyamoya disease, Security (finance), Institute for Health Metrics and Evaluation, Medical device, Pharmaceutical industry

This strategic venture between Cardio Diagnostics and Aimil seeks to address the growing prevalence of heart disease in India through the introduction of Cardio Diagnostics’ clinical test, PrecisionCHD, for the detection and personalized management of coronary heart disease (CHD).

Key Points: 
  • This strategic venture between Cardio Diagnostics and Aimil seeks to address the growing prevalence of heart disease in India through the introduction of Cardio Diagnostics’ clinical test, PrecisionCHD, for the detection and personalized management of coronary heart disease (CHD).
  • With Cardio Diagnostics’ PrecisionCHD test, there is a significant opportunity to reduce the burden of CHD across India.
  • “Heart disease is a global problem and Cardio Diagnostics’ expansion to India underscores our commitment to combat heart disease globally.
  • Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise.

ApiJect Systems, Corp. Bolsters Global Health Team with Esteemed Anthropologist and Leading Expert on Vaccine Hesitancy, Dr. Heidi J. Larson, as Senior Advisor

Retrieved on: 
Wednesday, October 4, 2023
Communication, Risk, Stuck: How Vaccine Rumors Start and Why They Don't Go Away, University, Institute for Health Metrics and Evaluation, BBC, Health education, University of Washington, World Health Organization's response to the COVID-19 pandemic, COVID-19, Senior advisor, ApiJect Systems, Research, Vaccine hesitancy, Doctor of Philosophy, Theory, UNICEF, Thought, Vaccine Confidence Project, Patient, Evaluation, Platform, Tropical medicine, Global North and Global South, Hygiene, Health, Immunization, Woman, Clinical, London School of Hygiene and Tropical Medicine, Management, Vaccine, Anthropology

Dr. Larson is best known for groundbreaking research that advances the medical, scientific, social, and political understanding of vaccine hesitancy.

Key Points: 
  • Dr. Larson is best known for groundbreaking research that advances the medical, scientific, social, and political understanding of vaccine hesitancy.
  • She has engaged in effective advocacy for better health education and policies by building consensus and critical partnerships that influence health interventions and shape policies.
  • She is the Founder and Director of The Vaccine Confidence Project, which since 2010 has worked throughout the world to overcome vaccine hesitancy.
  • She has published extensively on the topic, including her book, STUCK: How Vaccine Rumors Start—and Why They Don't Go Away.

Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf® in Taiwan and select South-East Asian markets

Retrieved on: 
Wednesday, September 13, 2023
Janus, Partnership, RA, Astellas Pharma, Prevalence, JAK, Disease, GBD, Menarini, Inflammation, Institute for Health Metrics and Evaluation, Person, Pain, Patient, Rheumatoid arthritis, Joint, Diagnosis, Castleman Disease Collaborative Network, IHME, Pharmaceutical industry, Tablet

Smyraf® has been approved in Taiwan and has patent protection for composition of matter until 2032.

Key Points: 
  • Smyraf® has been approved in Taiwan and has patent protection for composition of matter until 2032.
  • Subject to the terms of the agreement, Astellas will receive total payments of up to €5.5 million including upfront and milestone payments.
  • In addition, Menarini will pay Astellas a high-single digit percentage royalties on net sales of Smyraf®.
  • Menarini will have an option to extend the rights to select South-East Asian markets.

Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf® in Taiwan and select South-East Asian markets

Retrieved on: 
Wednesday, September 13, 2023
Janus, Partnership, RA, Astellas Pharma, Prevalence, JAK, Disease, GBD, Menarini, Inflammation, Institute for Health Metrics and Evaluation, Person, Pain, Patient, Rheumatoid arthritis, Joint, Diagnosis, Castleman Disease Collaborative Network, IHME, Pharmaceutical industry, Tablet

Smyraf® has been approved in Taiwan and has patent protection for composition of matter until 2032.

Key Points: 
  • Smyraf® has been approved in Taiwan and has patent protection for composition of matter until 2032.
  • Subject to the terms of the agreement, Astellas will receive total payments of up to €5.5 million including upfront and milestone payments.
  • In addition, Menarini will pay Astellas a high-single digit percentage royalties on net sales of Smyraf®.
  • Menarini will have an option to extend the rights to select South-East Asian markets.

Disregard Those Repeated Claims of Purported Funding Disparities Harming Charters

Retrieved on: 
Tuesday, September 12, 2023
LAUSD, University, National Education Policy Center, Policy, NEPC, New Jersey Policy Research Organization, Research, Multimedia, Language, Rutgers University, Organization, School, Literature, Student, Documentation, Publication, Education reform, Institute for Health Metrics and Evaluation, Pupil, Tutoring, Management

BOULDER, Colo., Sept. 12, 2023 /PRNewswire-PRWeb/ -- Over the past decade, pro-charter organizations have published a series of reports claiming that funding disparities put charter schools at a disadvantage compared to public schools run by school districts. However, those conclusions are invariably incorrect due to flawed research methods.

Key Points: 
  • BOULDER, Colo., Sept. 12, 2023 /PRNewswire-PRWeb/ -- Over the past decade, pro-charter organizations have published a series of reports claiming that funding disparities put charter schools at a disadvantage compared to public schools run by school districts.
  • Due to charter schools' substantial expansion in recent years, Weber also points out the importance of understanding and flagging such deceptive policy research.
  • Redirecting additional funding to charters based on advocacy reports using unreliable data and flawed methods may have adverse effects on other schools and state budgets.
  • Visit us at: http://nepc.colorado.edu
    Mark Weber, Rutgers University and the New Jersey Policy Perspective, (908) 358-5828, [email protected]
    View original content to download multimedia: https://www.prweb.com/releases/disregard-those-repeated-claims-of-purpor...

Study Finds Significantly More Adults Living with Diabetic Retinopathy in the United States than Previously Estimated

Retrieved on: 
Friday, June 16, 2023
Retina, Microsoft PowerPoint, University, Prevalence, Diabetes, Education, Visual impairment, Diabetic retinopathy, Centers for Disease Control and Prevention, Public, Policy, Eye, DR, Brain, Cell, Social media, Person, CDC, Vision, Ophthalmology, Institute for Health Metrics and Evaluation, Public health, NORC, Patient, Bleeding, Risk, University of Washington Department of Global Health, NORC at the University of Chicago, Mortality, Paratriathlon, MPH, White, IHME, Safety, Pharmaceutical industry, Medical device, Nursing, Soft drink, Toy, Dietary supplement, Doctor of Philosophy, JAMA Ophthalmology

CHICAGO, June 16, 2023 /PRNewswire-PRWeb/ --  A new study published today in JAMA Ophthalmology, "Prevalence of Diabetic Retinopathy in the US in 2021," found that in 2021, an estimated 9.6 million people in the United States (26.4 percent of those with diabetes) had diabetic retinopathy (DR), and 1.84 million people (5.1 percent of those with diabetes) had vision-threatening diabetic retinopathy (VTDR). The number of people aged 40 years and older living with diabetes-related eye disease more than doubled since prevalence was last estimated in 2004. VTDR has also almost doubled since last estimated in 2004.

Key Points: 
  • New study finds that nearly 10 million people in the US with diabetes have diabetic retinopathy.
  • The number of people aged 40 years and older living with diabetes-related eye disease more than doubled since prevalence was last estimated in 2004.
  • The study is the first of its kind to estimate the prevalence of DR and VTDR in people younger than 40 years.
  • For more information on the "The Prevalence of Diabetic Retinopathy in the United States In 2021" study or the VEHSS, visit https://www.cdc.gov/visionhealth/vehss/ .

Atlanta Neuroscience Foundation Marks World Neuroscience Day with Keynote Speaker Mark Richt, Former UGA Football Coach

Retrieved on: 
Tuesday, April 18, 2023
Hyatt, Optimism, Education, Culture, AAN, Roche, Health equity, Health, Quality of life, Hope, American Academy, Microsoft, UGA, Parkinson's Foundation, Research, DSM-IV codes, Life expectancy, Parkinson, MS, Alzheimer's disease, Institute for Health Metrics and Evaluation, Parkinson's disease, Epilepsy Foundation, Gates Ventures, Diagnosis, American Academy of Neurology, ANF, IHME, Past // Present // Future, Caregiver, Pharmaceutical industry, Nursing, Epilepsy

ATLANTA, April 18, 2023 /PRNewswire/ -- Mark Richt, former UGA football coach, will be the keynote speaker and open the conference with a conversation highlighting his journey living with Parkinson's.

Key Points: 
  • ATLANTA, April 18, 2023 /PRNewswire/ -- Mark Richt, former UGA football coach, will be the keynote speaker and open the conference with a conversation highlighting his journey living with Parkinson's.
  • Following the opening general assembly, attendees will have access to neurology specialists addressing medical advancements, research, education, and patient outcomes.
  • World Neuroscience Day is an awareness campaign and conference created by the Atlanta Neuroscience Foundation (ANF), an Atlanta-based 501c3.
  • World Neuroscience Day conference will be held Saturday, May 6, 2023, at Grand Hyatt Hotel-Buckhead from 8:00 am to 4:00 pm.

Outlook on the Enzyme Global Market to 2035: Players Include Adisseo, AB Enzymes, Amano Enzyme, BASF and Codexis - ResearchAndMarkets.com

Retrieved on: 
Friday, February 24, 2023
Health, Other Health, Diabetes, Glutamic acid, Food, ICMR, Protein, Cancer, Evaluation, Chronic pain, Indian Council of Medical Research, Sensation, Medical research, Public Health Foundation of India, Institute for Health Metrics and Evaluation, GMO, Pulse, Enzyme, Growth, Sciatica, MSG, Arthritis, Incidence, Type 2 diabetes, Prevalence, Fine chemical

Moreover, the high demand of enzymes in food and beverage industry is a key contributing factor for the market growth.

Key Points: 
  • Moreover, the high demand of enzymes in food and beverage industry is a key contributing factor for the market growth.
  • Moreover, the rising prevalence and incidence rates of chronic illnesses across the world is driving the growth of the enzyme at a substantial rate.
  • On the other hand, the immense concern related to the handling and safety issues of enzymes is constricting the market growth.
  • The global enzyme market is segmented into type, source, reaction type, and application.

Renalytix and Partners Awarded $10 Million Horizon Europe Grant to Advance Personalized Medicine in Treating CKD Throughout Europe and the United States

Retrieved on: 
Thursday, January 26, 2023
Prognosis, IE, Regent, University Medical Center Groningen, University of Michigan, Institute for Health Metrics and Evaluation, University of Leicester, Biomarker, SALT, European, DE, Valencian Community, Intellectual property, European Medicines Agency, Chronic kidney disease, Research, CKD, University, Patient, HIV disease progression rates, Dialysis, SE, FDA, LSE, Kidney failure, Precision medicine, Kidney disease, Innovative Medicines Initiative, Organization, Joslin Diabetes Center, Pharmaceutical industry

PRIME-CKD is funded by Horizon Europe, the European Union’s key funding program for research and innovation.

Key Points: 
  • PRIME-CKD is funded by Horizon Europe, the European Union’s key funding program for research and innovation.
  • The total budget of the project is $10 million over a projected five-year period with approximately 10% of the budget targeted for commercial translation activities to be undertaken by Renalytix.
  • The consortium brings together leading experts from 11 academic institutions, together with partners from patient representative foundations and regulatory agencies.
  • The PRIME-CKD consortium will further develop the evidence-based tools and roadmap to unlock the potential of precision medicine in the management of CKD.

Mahidol University, the Top University in Thailand, Has Officially Adopted Jolly Good's Medical VR

Retrieved on: 
Wednesday, November 30, 2022
COVID-19, Chakri Naruebodindra Medical Institute, Infection, Tropical medicine, Public health, Jane and Robert Cizik School of Nursing, Environment, Juntendo University, Institute for Health Metrics and Evaluation, Seven Is a Jolly Good Time, MHLW, Feel Good Inc., Zaporizhzhia Medical Academy of Post-Graduate Education Ministry of Health of Ukraine, Hospital, Ministry, Knowledge, Physician, Ramathibodi Hospital, Education, Faculty, Death, Evaluation, Faculty of Tropical Medicine, Mahidol University, Mahidol University, School, Chūō-ku, Ministry of Health, Labour and Welfare, ICT, VR, Public, Medicine, Pharmaceutical industry, Tutoring, Health, Nursing

TOKYO, Nov. 30, 2022 /PRNewswire/ -- Jolly Good Inc. (Chuo-ku, Tokyo, CEO: Kensuke Joji, hereinafter referred to as "Jolly Good"), in collaboration with Juntendo University (Bunkyo-ku, Tokyo, President: Hajime Arai), will commence a demonstration project for the introduction of medical education VR for the purpose of developing medical human resources through the use of VR at Royal Mahidol University (Bangkok, Thailand, President: Prof. Banchong Mahaisavariya, hereinafter referred to as "Mahidol University") and throughout Thailand. This is the first time that Japanese medical VR has been officially introduced into an overseas university.

Key Points: 
  • This is the first time that Japanese medical VR has been officially introduced into an overseas university.
  • In this project, Jolly Good will provide Mahidol University with VR teaching material production facilities and VR experience equipment to create an environment that enables the self-production of VR teaching materials for infectious disease treatment education at the university.
  • Year 1: Build a self-production environment for VR teaching materials at Mahidol University, complete the education program, and commence operation at the university.
  • In this seminar, professors from Mahidol University will give a remote VR lecture to medical students of Juntendo University in Japan by utilizing the educational VR of Infectious Disease Education produced at Mahidol University.